The search textbox has an autosuggest feature. When you enter three or more characters,
a list of up to 10 suggestions will popup under the textbox. Use the arrow keys
to move through the suggestions. To select a suggestion, hit the enter key. Using
the escape key closes the listbox and puts you back at the textbox. The radio buttons
allow you to toggle between having all search items start with or contain the text
you entered in the search box.
orantinib
An orally bioavailable receptor tyrosine kinase inhibitor. Orantinib binds to and inhibits the autophosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), thereby inhibiting angiogenesis and cell proliferation. Orantinib also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Code names: | | SU006668 SU6668 Sugen SU6668 TSU 68 | |
| |||
| Chemical structure: | | 3-(2,4-dimethyl-5-((2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-1H-pyrrol-3-yl)propionic acid | |
| |||
